Sharon Rosenzweig-Lipson at ARDD2025: LifeBiosciences

Sharon Rosenzweig-Lipson at ARDD2025: LifeBiosciences

by Sharon Rosenzweig-Lipson

Life & Natural Systems Medicine & Health MFKHHuman growth and developmentMFKH3Maturation and ageing
🎙 Sharon Rosenzweig-Lipson 👥 9K 📅 January 21, 2026 ⏱ 20 min 👁 197 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

partial epigenetic reprogrammingOSK factorsAAVglaucomaNAIONMASHDNA methylationclinical trial

Summary

Sharon Rosenzweig-Lipson, PhD, presents at the 12th Aging Research and Drug Discovery meeting on behalf of LifeBiosciences. She discusses their approach to partial epigenetic reprogramming using three Yamanaka factors (Oct4, Sox2, Klf4, without c-Myc) delivered via AAV vectors. The presentation covers their progress in optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with preclinical data in mice and non-human primates showing improved visual function, retinal ganglion cell survival, and epigenetic changes. They have completed GLP toxicology studies and plan to initiate a Phase 1 clinical trial in Q1 2026. Additionally, they present new data on a liver-targeted AAV (ER300) in a mouse model of MASH, showing improvements in liver enzymes, steatosis, and NAS score without body weight changes. The talk highlights the potential of partial epigenetic reprogramming to treat age-related diseases across multiple organs.

137 words

Critical Evaluation

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the application of partial epigenetic reprogramming for age-related diseases. The argumentation is based on preclinical data, including efficacy in animal models and safety assessments. The speaker clearly explains the mechanism and rationale, and the data presented support the potential of their approach. However, the evidence is primarily from animal studies and has not yet been published in peer-reviewed journals, so the strength of the argumentation is moderate.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is reasonable: the speaker references their own preclinical studies and mentions collaborations with Harvard Medical School, but specific citations are not provided in the talk. The title accurately reflects the content. The presentation is from a company scientist, so there is a potential conflict of interest, but the data appear to be presented transparently.

145 words

Title / Content Match

The title accurately reflects the content: a presentation by Sharon Rosenzweig-Lipson at ARDD2025 about LifeBiosciences' work.

Quality & Reliability

7/10

Presentation by a company scientist at a conference, describing preclinical data and upcoming clinical trials. Data is plausible but not peer-reviewed in this context; some claims are preliminary.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

Concurring Sources

Contribution & Novelties

The talk presents novel data on the use of partial epigenetic reprogramming for optic neuropathies and MASH, including new non-human primate data and preliminary liver data. The approach of using three Yamanaka factors (OSK) without c-Myc is highlighted as a safer alternative to full reprogramming.

Pour aller plus loin :

  • Yamanaka factors — Overview of the transcription factors used in cellular reprogramming.
  • Epigenetic reprogramming — General concept of resetting epigenetic marks.
  • AAV gene therapy — Background on AAV vectors used for gene delivery.
  • NAION — Clinical condition discussed in the talk.
  • MASH — Liver disease targeted by ER300.

98 words

Radar Profile

The radar profile shows high scores in technical level and information quantity, reflecting the specialized content and depth of data presented. The lower score in reliability is due to the preliminary nature of the data and lack of peer-reviewed publications.

Reliability 6/10

💬 No comments were provided for analysis.